U.S. Department of Health and Human Services Food and Drug Administration

## **MEDWATCH**

FORM FDA 3500A (10/15)

PLEASE TYPE OR USE BLACK INK

For use by user-facilities, importers, distributors and manufacturers for MANDATORY reporting

Page 1 of 3

Form Approved: OMB No. 0910-0291, E	Expires: 9/30/2018
See PRA stat	ement on reverse.
Mfr Report #	

Frequency	Route Used	
		FDA Use Only
17IIIIporter Report #		
F/Importer Report #		
Ifr Report #		
	See PRA:	statement on reverse.
Form Approved: C	NO. 09 10-029	1, Expires: 9/30/2018

		r ago r c	,, 0						FDA Use Only
	ts of "dd-mmm-yyyy" please use git year; for example, 01-Jul-2015		3.	Dose		Frequency	Route	e Used	
A. PATIENT INF	• • • • • • • • • • • • • • • • • • • •		#1 ■	250kg kilogr	am(s)	ltime(s)	2Day   Ep:	idural	
Patient Identifier	2. Age Year(s) Mon	h(a) 3. Sex 4. Weight	#2						
q.w	Week(s) Days	(-)							
q.w	or Date of Birth (e.g., 08 Feb 192		4. TI	herapy Dates (If	unknown. aiv	ve duration)	from/ 9. <b>E</b>	vent Abate	ed After Use
In Confidence		X Male X kg	to	(or best estimate	e)) (dd-mmm	-уууу)	S		Dose Reduced?
5.a. Ethnicity (Check	5.b. <b>Race</b> (Check all that ap		1├─	20-JUN-2019	2	1-JUN-20	19 #1	Yes _	No Doesn't
single best answer)	Asian American I	• • •	#2						apply
Hispanic/Latino	Black or African Americ		5. <b>D</b>   #1	iagnosis for Use	(Indication)		#2	Yes	_
☐ Not Hispanic/Latin	Native Hawaiian or Othe	er Pacific Islander	"						apply
B. ADVERSE E	VENT OR PRODUCT PRO	DBLEM	#2					Event Reap Reintroduc	ppeared After ction?
1. Adverse Ever		lem (e.g., defects/malfunctions)						Yes	
2. Outcome Attribute	ed to Adverse Event (Check all the		11.	the Product		ne Product	Over-		apply
	late (dd-mmm-yyyy):	_	11	ompounded?	-	-Counter?		Yes	No Doesn't
Life-threatening	Disab	ility or Permanent Damage	#1	Yes X N	lo #1 [	X Yes	No		apply
Hospitalization – i	initial or prolonged	enital Anomaly/Birth Defects	#2	Yes N	lo #2 [	Yes	No		
Other Serious (Im	portant Medical Events)		8. <b>E</b> :	xpiration Date (d	ld-mmm-yyy	y)			
Required Interven	ntion to Prevent Permanent Impair	ment/Damage (Devices)	#1			#2			
3. Date of Event (dd-	33337	is Report (dd-mmm-yyyy)	D.	SUSPECT M	EDICAL [	DEVICE			
	05	APR2021	1. <b>B</b>	rand Name					
5. Describe Event or			2.6	ommon Device N	Name .				2b. Procode
#1) Report terr	m:headache/LLT:/PT:		1 2. 0	ommon bevice i	vallie				20. Procode
			3. M	anufacturer Nam	ne. City and	State			
					,,				
		(Continuo on nogo 2)	4. <b>M</b>	odel#	L	ot#			perator of Device
6 Relevant Tests/La	boratory Data, Including Dates	(Continue on page 3)	<u> </u>	otolow #	-	vnivation D	oto (dd	—	lealth Professional
	,		'	atalog #			ate (dd-mmm- -		ay User/Patient
			S	erial #			tifier (UDI) #	c	Other
						•	, ,		
			6. <b>If</b>	Implanted, Give	Date (dd-mn	nm-yyyy) 7	'. If Explante	d, Give Da	te (dd-mmm-yyyy)
		(Continue on page 3)		_	_		_		
	story, Including Preexisting Medy, smoking and alcohol use, liver/li			this a single-use			П	res □ N	lo
unergies, pregnane	y, smoking and alcohol asc, livelin	duricy problems, etc.)	_	Yes to Item 8, Ei		·			
				,					
		(Continue on page 3)	10.1	Device Available	for Evaluat	ion2 (Do no	ot cond to ED	(4)	
C. SUSPECT PE	RODUCT(S)		_	Yes No		ed to Manuf		_	_
	rer/Compounder, Strength							<i></i>	
#1 — Name and Streng A multicenter phase trail	gth of novel inhibitor(G2Product001) with or	#1 – NDC # or Unique ID	111.0	Concomitant Me	dical Produ	cts and The	erapy Dates	(Exclude trea	atment of event)
without platinum chemot #1 - Manufacturer/Co	mpounder	#1 – Lot #							
G2BPS3637		201							
#2 – Name and Streng	gth	#2 – NDC # or Unique ID	1					(Contin	nue on page 3)
			E.	INITIAL REP	ORTER				
#2 - Manufacturer/Co	mpounder	#2 – Lot #	1. N	ame and Addres	s				
			Last	Name:			First Name:		
2. Concomitant Medi   Drug   Therapy	ical Products and Therapy Date Start and Stop Date   I	s (Exclude treatment of event) Dose   Indication	Add	ress:		T			
		,	City:			State	e/Province/Re	egion:	
	Country: ZIP/Postal Code:								
		(Continue on page 3)		ne #:		Email			
Submission of a re	port does not constitute an			ealth rofessional?	3. Occupati	on (Select fr	om list)	4. Initial Re Report t	Reporter Also Sent
personnel, user fac	cility, importer, distributor, i		1 –	Yes No				1 .	□ No □ Unk
caused or contribu	itea to the event.								

## MEDWATCH

FORM FDA 3500	A (10/1	<b>5)</b> (continu	ıed)			Pa	age 2 c	of 3						
F. FOR USE BY U  1. Check One  User Facility		ACILITY/II		RTER (De				1. Type of	CE MANUF		ERS ONL		. If Follow-up, What Type?	
3. User Facility or Impo								Se	ath rious Injury alfunction				Additional Information Response to FDA Req Device Evaluation	uest
1.0				S. Bl No.				□ No	t Returned to M	lanufacture	r		. Device Manufacture Date (dd-mmm-yyyy)	
4. Contact Person				5. Phone Nu	imber			☐ Ye	s Evalua o (Attach page t	ation Summa to explain w	-		. Labeled for Single Use?	
6. Date User Facility or Importer Became Av of Event (dd-mmm-y)	ware	Type of Re				This Report			ovide code:	aluation Co	odes (Refer	r to codir	Yes No	
		Follow-up	_				== /		Patient		<u> т</u> г	-		
9. Approximate Age of Device	10. Event	Problem Co	des (/	Refer to codin	ng manu	ıal)			Code					
	Patient Code			-					Device Code			_	-	
	Device Code		_	•		-			Method		]-		-	
11. Report Sent to FDA enter date (dd-mmm			catio ospita	n Where Eve		Outpatient			Results				-	
			ome			Diagnostic Facil Ambulatory			Conclusions		]-	-	-	
13. Report Sent to Mar Yes, enter date (dd-		? (If   _ 0	utpati	g Home ent Treatmen		Surgical Facility	'		dial Action Initi	_		8. <b>Us</b>	age of Device  Initial Use of Device	
Yes		l	acility ther:							Notification			Reuse	
☐ No					(Spec	cify)		0 0 22	pair	Inspection Patient M			Unknown	
G. ALL MANUFA	CTURE	RS			10			Ott	ner:ditional Manuf	Adjustme			USC 360i(f), list correction/ noval reporting number:  or 11. Corrected I	 Data
1. Contact Office (and	Manufactu	ıring Site for	Devi	ces)	2. Pho	ne Number								
Name					1	11000	N.							
Address				+		ort Source eck all that app	(y)							
					Fo	reign	2-							
					St	udy								
					Lit	erature								
Email Address						onsumer								
			1.,			ealth Profession	ial							
Compounding Outsour	cing Facility	y 503B?	Yes		1=	ser Facility								
4. Date Received by Manufacturer (dd-mi	тт-уууу)	NDA			Re	ompany epresentative stributor								
6. If IND, Give Protocol		ANDA				her:		- 1						
o. II IND, GIVE PTOLOCO	"	BLA						$\cup$ $\setminus$						
(		PMA			-		-							
7. Type of Report (Check all that apply)		510(k)	#											
5-day 30-da	ay	Combin												
7-day Perio		I	oduct -1938											
10-day Initial	w-up #	116	OTC											
15-day Follo	w-up #													
9. Manufacturer Repor	t Number	8. Advers	se Eve	ent Term(s)										

This section applies only to requirements of the Paperwork Reduction Act of 1995.

The public reporting burden for this collection of information has been estimated to average 73 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov

OMB Statement: "An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number."

FDA USE ONLY

Please DO NOT RETURN this form to the above PRA Staff email address.



## MEDWATCH

(CONTINUATION PAGE)

For use by user-facilities,
importers, distributors, and manufacturers
for MANDATORY reporting

Page 3 of 3

	-ORM FDA 3500A (10/15) (Continued)
	B.5. Describe Event or Problem (continued)
<u> </u>	
2000	
3	
<u> </u>	
1	
	B.6. Relevant Tests/Laboratory Data, Including Dates (continued)
?	
2	
3	
חמכע נס ונפווו	
۳	
	B.7. Other Relevant History, Including Preexisting Medical Conditions (e.g., allergies, pregnancy, smoking and alcohol use, hepatic/renal dysfunction, etc.) (continued)
i	
Dack to Item	
3	
ار	
	Concomitant Medical Products and Therapy Dates (Exclude treatment of event) (For continuation of C.2 and/or D.11; please distinguish)
3	
4	
Dack to item D. I.I.	
	Other Personalis
2	Other Remarks
•	